Tag:

flu vaccine

Latest Headlines

Latest Headlines

Novavax reports PhII success for quadrivalent seasonal flu vax

Novavax is making waves in the influenza space, reporting positive Phase II results for its quadrivalent seasonal flu vaccine on Thursday.

NIAID scientists one step closer to 'universal' flu vaccine

A vaccine against a wide range of flu viruses has long eluded scientists, but NIAID researchers have discovered what could be the foundation of a 'universal' flu vaccine.

Study: Flublok is more effective than traditional flu shot

Protein Sciences released data showing that Flublok Quadrivalent--its follow-up to the FDA-approved trivalent Flublok--outperformed the traditional egg-based quadrivalent vaccine.

Move over, India--China can make WHO-approved vaccines, too

China's growing vaccine industry scored again on Friday when the World Health Organization announced that it had approved a Chinese flu vaccine.

Manufacturing key to getting more effective flu jabs to market faster

With the effectiveness of this year's influenza vaccines so low as to have made most of this year's vaccinations pointless, the industry is searching for avenues to abbreviate the 6-month development and manufacturing process to deal better with the kinds of virus mutations that came into play this year.

UPDATED: Novartis' Fluad off the hook in Italy following 19 deaths

After last week partially banning Novartis' Fluad, Italian officials now say tests on the flu vaccine show the product is safe.

Sanofi, Protein Sciences win flu jab nods in older adults

A couple of flu vaccine makers have new patient populations to target, thanks to a pair of recent FDA approvals in older adults.

Production issues for GSK, Sanofi delay flu vaccines in the U.S.

A Sanofi spokesperson told The Wall Street Journal that it has delayed some forms of its Fluzone because the flu strains used to produce the shot did not grow as fast as expected. A GSK spokesman said in an email Monday that it has cut its production targets to 26 million to 27 million doses for the U.S. from the 28 million to 33 million doses originally anticipated.

Novartis officially bows out of vaccines with flu sale to CSL

Novartis' 8-year foray into vaccines is officially coming to a close. After divesting the bulk of its unit to GlaxoSmithKline in an April deal, the pharma giant Sunday announced it had agreed to sell its flu shot business to Australia's CSL. And with that, it'll make its exit from a field that's given it trouble since its Chiron buyout in 2006.

New problems at GSK flu vaccine plant will impact U.S., Canada orders

GlaxoSmithKline's Canadian flu vaccine plant has been in the spotlight recently for problems that spurred an FDA warning letter and a talking-to from Health Canada. But it's different problems that the British drugmaker now says will keep it from filling about 30% of its Canadian order for this season--and they could compromise some of its U.S. shipments, too.